<DOC>
	<DOCNO>NCT00232193</DOCNO>
	<brief_summary>The purpose study determine whether give intravenous dexamethasone every 4 week first 12 month weekly Avonex dose reduce progression functional impairment , brain atrophy , relapse rate frequency , new enlarge brain lesion first 24 month Avonex therapy patient relapsing-remitting mono-symptomatic multiple sclerosis .</brief_summary>
	<brief_title>Safety/Effectiveness Adding Monthly Dexamethasone Weekly Avonex MS</brief_title>
	<detailed_description>Beta Interferon-1a ( Avonex ) approve FDA 1996 treat relapsing-remitting multiple sclerosis . Clinical trial show evidence reduction relapse progression neurological cognitive disability use Avonex , well reduction brain atrophy new MS lesion MRI observe . Despite , Avonex abolish disease activity , therefore , frequent need adjunctive therapy , short course corticosteroid . This study research value add monthly pulse corticosteroid adjunctive therapy first year Avonex use determine : ) safety tolerability b ) therapy reduce progression functional impairment , c ) therapy reduce progression whole brain atrophy 13 month observation period .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>male female patient age 1855 year inclusive provide informed consent screen study diagnosis MS meet McDonald diagnostic criterion RRMS CHAMPS criterion CIS EDSS score 0.03.5 immunomodulator cytoxic agent steroids immunosuppressant within 30 day prior Baseline Visit must brain MRI scan demonstrating lesion consistent MS T2weighted FLAIR image subject must willing able participate aspect study , include use study medication prescribe , screen followup clinical MRI assessment type I type II diabetes uncontrolled hypertension ( systolic &gt; 160 diastolic &gt; 100 despite medication therapy ) history suicidal ideation history psychosis history alcoholism substance abuse clinically significant coronary artery disease history hepatic failure chronic renal failure history cancer basal squamous cell carcinoma skin pregnancy unwillingness use adequate precaution prevent pregnancy duration study nurse mother history stroke , dementia , seizure disorder , peripheral neuropathy , Parkinsonism , myasthenia , myelopathy primary degenerative disease central peripheral nervous system history peptic ulcer disease history intolerance corticosteroid allergy albumin history osteoporosis history Lupus , Sjogrens syndrome , Lyme disease syphilis abnormal laboratory result indicative significant hepatic , renal , hematopoetic , coagulation dysfunction entity disease entity , opinion investigator would potentially prevent patient successfully complete 2 year participation trial confound observation make trial prior use Avonex , Betaseron , Rebif , mitoxantrone , cyclophosphamide , azothioprine , methotrexate , cladribine , cyclosporin , CellCept , IVIG , natalizumab , anti Tcell anti Bcell antibody , plasmapheresis systemic immunosuppressant cancer chemotherapeutic agent unwillingness inability comply requirement protocol know diagnosis osteoporosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Interferon Beta 1-a</keyword>
	<keyword>Pulsed steroid</keyword>
</DOC>